SavedAdd your journal

Journals / Annals of Medical Research / 2018 / Cilt: 25 - Sayı: 4

Nevirapine mitigates monosodium glutamate induced neurotoxicity and oxidative stress changes in prepubertal mice

Adejoke Yetunde ONAOLAPO
Olakunle James ONAOLAPO
Pages
518–524
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

On day 28, animals were euthanized and blood was collected for estimation of plasma malondialdehyde (MDA) and antioxidant levels; while sections of the cerebrum and hippocampus were either fixed and processed for general histology, or homogenized for the estimation of brain biochemical parameters.Results: Results showed that administration of nevirapine alone (or when co-administered with MSG) was associated with a reduction in weight gain, increase in plasma/brain MDA levels, morphologic/morphometric evidence of dose-related hypercellularity; and varying degrees of neuroprotection, with co-administration.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: We investigated the effects of nevirapine on changes in body weight, lipid peroxidation/antioxidant status, apoptotic markers and neuromorphology following monosodium glutamate-induced neurotoxicity in prepubertal mice.Material and Methods: Eighty male mice which were randomly divided into eight groups of ten mice each (n=10) were used.
📊
Key Findings & Data:Mice in each group were administered oral vehicle, monosodium glutamate (MSG) at 2g/kg, or one of three doses of nevirapine (at 7.5, 15 and 30 mg/kg) alone or co-administered with MSG.
💡
Conclusion & Impact:On day 28, animals were euthanized and blood was collected for estimation of plasma malondialdehyde (MDA) and antioxidant levels; while sections of the cerebrum and hippocampus were either fixed and processed for general histology, or homogenized for the estimation of brain biochemical parameters.Results: Results showed that administration of nevirapine alone (or when co-administered with MSG) was associated with a reduction in weight gain, increase in plasma/brain MDA levels, morphologic/morphometric evidence of dose-related hypercellularity; and varying degrees of neuroprotection, with co-administration.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: We investigated the effects of nevirapine on changes in body weight, lipid peroxidation/antioxidant status, apoptotic markers and neuromorphology following monosodium glutamate-induced neurotoxicity in prepubertal mice.Material and Methods: Eighty male mice which were randomly divided into eight groups of ten mice each (n=10) were used. Mice in each group were administered oral vehicle, monosodium glutamate (MSG) at 2g/kg, or one of three doses of nevirapine (at 7.5, 15 and 30 mg/kg) alone or co-administered with MSG. Vehicle or nevirapine were administered daily for 28 days, while MSG was administered on days 1-7. On day 28, animals were euthanized and blood was collected for estimation of plasma malondialdehyde (MDA) and antioxidant levels; while sections of the cerebrum and hippocampus were either fixed and processed for general histology, or homogenized for the estimation of brain biochemical parameters.Results: Results showed that administration of nevirapine alone (or when co-administered with MSG) was associated with a reduction in weight gain, increase in plasma/brain MDA levels, morphologic/morphometric evidence of dose-related hypercellularity; and varying degrees of neuroprotection, with co-administration. Nitric oxide levels and caspase-3 activity increased only with MSG, while superoxide dismutase activity decreased.Conclusions: In conclusion, subchronic administration of nevirapine was associated with dose-related alterations of the measured parameters; indicating possible neuroprotection and mitigation of MSG neurotoxicity at some of the doses studied.

🔖

Cite This Article

ONAOLAPO, A. Y., ONAOLAPO, O. J. (2022). Nevirapine mitigates monosodium glutamate induced neurotoxicity and oxidative stress changes in prepubertal mice. Annals of Medical Research, Cilt: 25 - Sayı: 4, 518–524. https://ajindex.com/articles/447285

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Nikanjam M, Kabamba D, Cressey TR, et al. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrob. Agents Chemother 2012;56:5374-80. de Bethune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res 2010;85:75-90.
  2. Milinkovic A, Martinez E. Nevirapine in the treatment of HIV. Expert Rev. Anti Infect Ther 2004;2:367-73. FDA (U. S. Food and Drug Administration) Viramune (nevirapine) prescribing information. 2010; http://www.accessdata.fda.gov/drugsatfda_
  3. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1- infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002;29:484-94.
  4. Mas CM, Miller TL, Cordero C, et al. The effects of foetal and childhood exposure to antiretroviral agents. J AIDS Clinic Res 2011;2:001. Chou M, Bertrand J, Segeral O, et al. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. Antimicrob Agents Chemother 2010;54:4432-9.
  5. King JR, Nachman S, Yogev R, et al. Efficacy tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. Paediatr. Infect. Dis. J. 2005;24:880-5.
  6. Chokephaibulkit K, Cressey TR, Capparelli E, et al. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. Antivir. Ther 2011;16:1287-95.
  7. Shenton JM, Teranishi M, Abu-Asab MS, et al. Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res Toxicol 2003;16:1078-89.
  8. Shenton JM, Popovic M, Chen J, et al. Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem Res Toxicol 2005;18:1799-813.
  9. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998;20:1071-92.
  10. Hall DB, MacGregor TR, Case-control exploration of relationships between early rash or liver toxicity and plasma concentrations of nevirapine and primary